Business Wire·May 14, 2026, 7:30 AM ET

Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Zura Bio Limited granted Muzammil Mustufa, its new Chief Business Officer, an inducement award on May 13, 2026, consisting of an option to purchase up to 600,000 Class A Ordinary Shares.
The award was approved by the Compensation Committee outside the 2023 Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The option has an exercise price of $4.80 per share, equal to the closing price of Zura's Class A Ordinary Shares on the grant date.
Vesting occurs over four years, with 25% vesting on the one-year anniversary of the commencement date, followed by equal quarterly installments contingent on continuous service.
Zura is a clinical-stage company developing dual-pathway antibodies for autoimmune & inflammatory diseases.
Lead candidate tibulizumab (ZB-106) is being evaluated in Phase 2 studies: TibuSHIELD for hidradenitis suppurativa & TibuSURE for systemic sclerosis.
Additional candidates torudokimab (ZB-880) & crebankitug (ZB-168) have completed Phase 1/1b studies & are under evaluation for various conditions.